P53 regulates the migration of mesenchymal stromal cells in response to the tumor microenvironment through both CXCL12-dependent and -independent mechanisms

SIANG-YO LIN¹, SONIA C. DOLFI², SOHRAB AMIRI², JAILONG LI¹, TULIN BUDAK-ALPDOGAN³, KUO-CHIEH LEE³, CHRISTOPHER DERENZO¹, DEBABRATA BANERJEE²,³ and JOHN GLOD¹,²

Departments of ¹Pediatrics, ²Pharmacology and ³Medicine, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903, USA

Received May 14, 2013; Accepted June 19, 2013

DOI: 10.3892/ijo.2013.2109

Abstract. Mesenchymal stromal cells (MSCs) are multipotent fibroblast-like cells located in the bone marrow that localize to areas of tissue damage including wounds and solid tumors. Within the tumor microenvironment, MSCs adopt the phenotype of carcinoma-associated fibroblasts (CAFs) and stimulate tumor growth. Production of the chemokine CXCL12, also known as stromal cell-derived factor 1 (SDF-1), by MSCs is required for their in vitro migration in response to tumor cells and has also been implicated in stimulation of tumor growth. The tumor suppressor p53 regulates cellular migration, CXCL12 production and the promotion of tumor growth by carcinoma-associated fibroblasts (CAFs). We investigated the role of p53 in MSC migration to tumors. P53 inhibits the migration of MSCs in response to tumor cells in conjunction with a decrease in CXCL12 transcription. Conversely, decreased p53 activity leads to enhanced MSC migration. Interestingly, increased p53 activity inhibits MSC migration even in the context of high concentrations of exogenous CXCL12. These data show that stromal p53 status impacts the recruitment of MSCs to solid tumors through both regulation of CXCL12 production as well as other mechanisms. Stromal p53 may influence other important aspects of tumor biology such as tumor growth and metastasis through mechanisms distinct from CXCL12.

Introduction

Mesenchymal stromal cells (MSCs) are multipotent cells that can be mobilized from the bone marrow and other tissues and localize to sites of inflammation including tumors and areas of injury (1-11). They have the capacity to differentiate into mesenchymal cell types including adipocytes, chondrocytes and myocytes (5). Upon incorporation into the stroma, MSCs promote tumor growth and metastasis (11,12). The molecular mechanisms regulating the mobilization and homing of MSCs to tumors have not been completely defined.

CXCL12 is a chemokine that is produced by stromal cells and is required for the migration of MSCs and tumor cells in response to each other (9,14). Additionally, CXCL12 is produced by carcinoma-associated fibroblasts (CAFs) and plays a role in tumor growth and progression (14). In vitro, tumor cells stimulate MSC motility and, over time, induce MSCs to adopt a carcinoma-associated fibroblast phenotype (9,12). Because p53 activity impacts cell mobility in fibroblasts (23,24) and may also play a role in the differentiation of mesenchymal cells (25) it is reasonable to suggest that p53 status influences the interaction between neoplastic and stromal cells. One mechanism for p53 regulation of tumor/stromal interaction is through modulation of CXCL12 production. Induction of MSC migration by tumor cells and stimulation of tumor growth by fibroblasts are dependent on stromal CXCL12 production (9,14).

In vitro, tumor cells stimulate MSC motility and, over time, induce MSCs to adopt a carcinoma-associated fibroblast phenotype (9,12). Because p53 activity impacts cell mobility in fibroblasts (23,24) and may also play a role in the differentiation of mesenchymal cells (25) it is reasonable to suggest that p53 status influences the interaction between neoplastic and stromal cells. One mechanism for p53 regulation of tumor/stromal interaction is through modulation of CXCL12 production. Induction of MSC migration by tumor cells and stimulation of tumor growth by fibroblasts are dependent on stromal CXCL12 production (9,14).

Our data show that p53 regulates MSC motility. Increased p53 levels inhibit MSC mobility in response to tumor cells. The influence of p53 on MSC motility may be mediated, in part, through the transcriptional regulation of CXCL12. Conversely, MSCs with p53 knock-down show increased migration to tumor cells in vitro as well as to in vivo tumors. Interestingly,
MSCs with increased p53 do not show increased migration in response to tumor conditioned media, even in an environment with a high concentration of exogenous CXCL12. This suggests that p53 is involved in other aspects of tumor/stromal interaction distinct from CXCL12 production. Our study demonstrates that stromal p53 status influences important aspects of the response of MSCs to tumor cells and provides additional insight into the molecular systems that regulate this interaction.

Materials and methods

Reagents and cell lines. C57BL/6J p53+/− mice were generously provided by Dr Arnold Levine. C57BL/6J wt mice were purchased from Charles River Laboratories (Wilmington, MA, USA). Nude mice were purchased from Taconic Farms (Hudson, NY, USA). All animal procedures were approved by the Animal Care and Use Committee of RWJMS. MDA-MB231 cells were obtained from American Type Culture Collection (Manassas, VA, USA http://www.atcc.org); pooled human MSCs were obtained from Lonza (Walkersville, MD, USA, http://www.lonza.com) and used in early passage (below passage 8). MDA-MB231 cells were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) and 100 U/ml penicillin G and 100 µg/ml streptomycin at 37°C in 5% CO2. Human MSCs were expanded in MesenCult media with hMSC stimulatory supplements (Lonza) and 10% FBS. Antibodies used in these studies included p53 (SC263) (Santa Cruz Biotechnology, Santa Cruz, CA, USA); α-tubulin and p21 (Sigma-Aldrich, St. Louis, MO, USA); GAPDH (Treivgen, Gaithersberg, MD, USA).

Transwell chamber migration assay. A Falcon cell culture insert system along with companion 24-well tissue culture plate was used for the chemotaxis assay as described previously (9). The polyethylene terephthalate membrane, pore size 8 µm, was selected to allow passage of mammalian cells. The insert was removed aseptically and placed in the notch of each well using forceps. MSCs (1-2×10⁶) were plated in 500 µl of α-MEM (Invitrogen) supplemented with 10% heat-inactivated FBS and 1% penicillin/streptomycin, placed in the insert (top chamber). The bottom chamber contained either conditioned medium from tumor cells or control medium (DMEM containing 2% FBS and penicillin/streptomycin). Migration assays were stopped after 16 h and cells remaining on the top of the membrane were removed with a wet cotton swab. MCSs that had migrated through the membrane were stained with crystal violet. Stained cells were counted under high power magnification (x40). For some experiments Nutlin-3 (Sigma-Aldrich, St. Louis, MO, USA) or recombinant CXCL12 (R&D Systems, Minneapolis, MN, USA) were added to both the upper and lower chambers to the indicated final concentrations.

Knockdown of p53 and CXCL12 in hMSCs using siRNA and lentiviral short hairpin RNA. Human MSCs (1.5×10⁶ cells) were plated in α-MEM (Invitrogen) with 10% FBS. After overnight incubation hMSCs were transsected with small interfering RNA (siRNA) specifically targeting p53 or CXCL12 or a scrambled sequence serving as a control (Thermo Scientific) using Lipofectamine 2000 (Invitrogen). Experiments were performed 2 days after transfection. Expression constructs containing short hairpin RNA (shRNA) sequences targeting p53 were obtained from Santa Cruz. hMSCs were infected using the manufacturer’s protocols and the knockdown of p53 was confirmed by western blotting. Cells were allowed to recover for 24 h prior to performing experiments.

Production of conditioned medium from MDA-MB-231 cells. To obtain tumor conditioned medium, a ratio of 7.5×10⁶ tumor cells/700 µl of DMEM containing 2% heat-inactivated FBS and 1% penicillin/streptomycin (Invitrogen) were incubated overnight. Conditioned medium was collected and spun down at 1,200 rpm to remove cellular debris. Supernatant was filtered through a 0.45-µm sterilif filter (Millipore, Billerica, MA, USA) prior to use in experiments.

Western blotting. Human MSCs were cultured to 80% confluence in a 150-mm tissue culture dish. Cells were then treated with MDA-MB231 conditioned medium or control medium with 25 µM Nutlin-3 or vehicle [dimethyl sulfoxide (Sigma-Aldrich)] for 6 and 24 h. Following this treatment, cells were scraped from the dish and re-suspended in 200 µl of radioimmunoprecipitation assay (RIPA) buffer plus 10 µg/ml aprotinin, 10 µg/ml leupeptin and 1 mM phenylmethylsulfonyl fluoride (PMSF). After clearing the cell lysates by centrifugation (16,000 g, 20 min at 4°C), the protein concentration was determined (Pierce, IL, USA). After boiling for 10 min, lysates (20 µg) were resolved by SDS-polyacrylamide gel electrophoresis, transferred onto PVDF membrane (Millipore) and visualized by immunoblotting with antibodies of interest.

Quantitative reverse transcription-PCR for SDF-1. Human MSCs were treated with Nutlin-3 as described above. Cells were then collected and RNA was extracted from MSCs using the RNeasy Mini kit (Qiagen Inc., Valencia, CA, USA) following standard procedures and quantified using the NanoDrop (Thermo Fisher Scientific, Rockford, IL, USA). Messenger RNA (mRNA) was used to generate complementary DNA (cDNA) which was amplified with a one-step RT-PCR kit (Applied Biosystems Inc., Foster City, CA, USA) using the MX4000 Multiplex Quantitative PCR System (Stratagene, Cedar Creek, TX, USA). CXCL12 cDNA was amplified by a CXCL12 taqman gene expression assay (Hs00930455, Applied Biosystems Inc., Foster City, CA, USA) using 100 ng of total RNA as starting material. 18s rRNA was amplified by the internal control 18s rRNA taqman assay (Applied Biosystems Inc.) using 1 ng of total RNA. Each RNA sample was assayed in quadruplicate and relative cDNA levels were determined after normalization to the internal 18s rRNA control.

In vivo migration of MSCs to tumors. MSCs were isolated from the bone marrow of C57BL/6J p53+/− mice as previously described (9). Briefly, mice were euthanized using bottled CO2 inhalation and the bilateral femurs were dissected out using sterile technique. The femurs were washed in phosphate-buffered saline containing 2% fetal bovine serum (FBS). Bone marrow cells were then obtained by flushing the femurs with PBS with 2% FBS. Cells were then filtered through a 70-µm nylon mesh and plated in α-MEM with 10% FBS and penicillin/streptomycin and cultured for seven days and then
used in experiments. For use as a control, murine MSCs were transfected with wild-type murine p53. The p53 wild-type (wt) expression plasmid was the generous gift of Dr Arnold Levine. The p53-wt plasmid has been previously described and encodes murine p53 and G418 resistance with an SV40 origin of replication (26). Wild-type MSCs were labeled using carboxyfluorescein diacetate succinimidyl ester (CFSE) (Invitrogen) and p53 knockout MSCs were labeled using CellTracker CM-Dil (Invitrogen) according to the manufacturer's instructions. The breast cancer cell line MDA-MB-231 (American Type Culture Collection) was used in this study. Cells (10⁶) along with Matrigel (50 µl per injection; BD Biosciences) were injected subcutaneously into nude mice and tumors were allowed to reach a size of ~5 mm in diameter. At this point, CFSE-labeled murine MSCs expressing human p53 and CM-Dil-labeled murine p53-/- MSCs were mixed at a ratio of 1:1. Mixed MSCs (5×10⁶) were then injected subcutaneously 10 mm from each tumor. Seven days later the mice were sacrificed using CO₂ inhalation. Tumors were dissected from the mice and a single cell suspension of each tumor was made. Tumors were dissected into small pieces using a scalpel and dissociated using collagenase (Roche, Mannheim, Germany) (0.035% wt/vol) in α-MEM at 37˚C for 1 h. Tissue was further dissociated by pipetting several times through a 5cc pipette and debris was removed using a nylon strainer. The single cell suspension was then washed with α-MEM with 10% FBS. The cellular component of each tumor was then analyzed using flow cytometry.

Statistical analysis. At least three independent experiments were performed for each in vitro migration assay. Results are presented as the means ± standard deviation. Statistical significance was determined using the Student's t-test and a value of P<0.05 was considered statistically significant. Microsoft Excel software was used for statistical analysis.

Results

Regulation of MSC migration by p53. Human MSCs were treated with the murine double minute 2 (MDM2) antagonist, Nutlin-3, leading to expected increases in p53 as well as increases in the p53 target p21 (Fig. 1A). In conjunction with increased p53 levels, the in vitro migration of MSCs in response to MDA-MB-231 tumor cells was decreased. The migration to tumor conditioned media showed a non-significant trend toward decreasing and Nutlin-3 did not inhibit the migration of MSCs in response to interleukin 8 (IL-8) (Fig. 1B). There was minimal basal migration of MSCs in response to control medium and this was not changed by treatment with Nutlin-3. When levels of p53 were decreased using siRNA (Fig. 1C), MSCs exhibited increased migration in response to tumor cells (Fig. 1D). These results suggested that p53 plays a role in regulating the response of MSCs to tumor cells.

Exposure to tumor-conditioned medium does not influence MSC p53 activity. hMSCs were exposed to a combination of Nutlin-3 and MDA-MB-231 conditioned medium. As expected, exposure of MSCs to nutlin-3 led to increased levels of p53 as well as its target p21. However, exposure of MSCs to tumor conditioned medium did not impact p53 levels (Fig. 2). This
result indicates that, while the p53 level influences MSC migration in response to tumor cells, induction of MSC motility by TCM is not mediated by changes in p53 activity.

**Increased p53 level leads to decreased CXCL12 production by MSCs.** We next explored the mechanism of regulation of MSC migration by p53. Because production of CXCL12 by MSCs is required for their migration in response to tumor cells (9), we investigated the effect of increased p53 on CXCL12 production by MSCs. Nutlin-3 treatment decreased hMSC CXCL12 mRNA levels after 24 h. CXCL12 mRNA levels in MSCs exposed to conditioned medium from MDA-MB-231 cells were decreased by nutlin-3 treatment at both 6- and 24-h time intervals (Fig. 3). These data suggested that p53 impacts MSC migration through regulation of CXCL12 transcription.

**The increased motility of MSCs due to p53 knock-down is dependent on CXCL12.** To further demonstrate the mechanism of action for Nutlin-3 inhibition of MSC chemokinesis, MSCs with p53-knockdown were treated with Nutlin-3. Knock-down of CXCL12 production using siRNA decreased the migration of p53-/- MSCs suggesting that decreased p53 activity leads to increased MSC mobility through increased CXCL12 transcription. (n=4) (P=0.007).

**P53 regulates MSC migration using multiple mechanisms.** We then sought to determine whether the effect of p53 levels on MSC migration was exclusively through its role in the
regulation of CXCL12 production. Recombinant CXCL12 protein was added to human MSCs that had been treated with Nutlin-3. While exogenous application of CXCL12 does stimulate migration of MSCs in response to tumor conditioned medium (9), recombinant CXCL12 failed to increase migration of MSCs treated with Nutlin-3 (Fig. 5). This result suggests that, in addition to regulating the production of CXCL12, p53 may impact MSC migration through additional mechanisms.

The in vivo homing capability of p53-null MSCs to tumors is enhanced compared to wild-type. To determine whether p53 regulates homing of MSCs to tumor sites in vivo, we used bone marrow-derived MSCs isolated from p53-null mice. The human wild-type p53 gene was introduced into the MSCs using a lentiviral vector. Western blot analysis demonstrated that MSCs isolated from p53-null animals were deficient in p53 protein and that after transfection of wild-type p53 gene, the expression of the tumor suppressor was detected (Fig. 6A). Wild-type MSCs were labeled using CFSE and p53 knockout MSCs were labeled using CM-Dil. Wild-type and p53−/− MSCs were mixed in a 1:1 ratio and subcutaneously co-injected into nude mice 5 mm from established tumors (MDA-MB231). At day 7 after administration of the MSCs, animals were sacrificed and tumors were collected and used to generate single cell suspensions. The ratio of wild-type to p53−/− cells in the tumor was then determined using flow cytometry. Increased number of p53-null MSCs were found in the tumors compared to wild-type MSCs, indicating that the in vivo homing capability of MSCs was enhanced in cells with decreased p53 activity (Fig. 6B).

**Migration of MSCs in response to Tumor CM was significantly decreased in the presence of Nutlin-3 (P<0.005).**

Figure 5. Decreased MSC motility in response to increased p53 activity is not reversed by CXCL12. MSCs were treated with 25 µM Nutlin-3. Recombinant CXCL12 was added to both the upper and lower chambers of the Boyden chamber and migration of MSCs in response to MDA-MB-231 cell conditioned media was then allowed to proceed overnight. Exogenous CXCL12 did not reverse the decreased migration of MSCs observed with Nutlin-3 treatment. **Migration of MSCs in response to Tumor CM was significantly decreased in the presence of Nutlin-3 (P<0.005).**

Figure 6. MSCs with p53 knock-down localize more efficiently to tumors in vivo than MSCs with wild-type p53. Murine MSCs were isolated from C57BL/6J p53−/− mice. In order to generate cells with functional p53, murine p53−/− cells were transfected with a plasmid encoding wild-type murine p53. (A) Western blot analysis of protein isolated from p53−/− murine cells and p53-transfected murine cells shows expression of human p53. (B) MSCs expressing wt p53 and p53−/− MSCs were differentially labeled using green (CFSE) and red (CM-DiI) fluorescent dyes, respectively. The cells were combined in a ratio of 1:1 and subcutaneously co-injected into nude mice 5 mm from established tumors (MDA-MB231). An increased percentage of labeled p53 knockdown MSCs were present in the tumors compared to wild-type MSCs, indicating that the in vivo homing capability of MSCs was enhanced in cells with decreased p53 activity (Fig. 6B).
Discussion

Carcinoma associated fibroblasts are known as a key mediator of tumor growth and progression. A better understanding of signaling pathways underlying communication between neoplastic cells and MSCs is important to better define their role in tumor biology. MSCs are mobilized from bone marrow and other tissues and integrate into the tumor stroma (2.7.9.12). They impact diverse aspects of tumor progression such as angiogenesis, tumor growth and metastasis (11,12,27). While there are likely to be multiple mechanisms for the intercellular signaling between MSCs and tumor cells, the chemokine, CXCL12 has been implicated in MSC chemotaxis and homing to tumors, MSC-mediated stimulation of tumor growth and cellular tissue invasion (9,14,27,28).

Recently, Addadi and colleagues demonstrated that CXCL12 production is downregulated in tumor stromal fibroblasts by p53 and that this change in the stroma has a significant impact on tumor growth (14). Importantly, it has also been shown that systemically delivered p53-deficient MSCs decrease tumor latency (14,16), providing further evidence that the stromal p53 status is important in tumor growth.

Clinical studies have reinforced the potential role of p53-mediated signaling in tumor/stromal interactions. TP53 mutations have been reported within the stroma of sporadic breast cancers (19) and both TP53 mutation as well as p53 expression in stromal fibroblasts are associated with lymph node metastasis in breast cancer (19,29). Others have found that changes in the stromal expression of the p53 target, p21, is associated with increasing malignancy in breast cancers as well as an increased growth rate of human breast cancer xenografts when tumors are implanted along with p21 deficient fibroblasts (30). Interaction with cancer cells can influence the p53 status of fibroblasts. Co-culture with the small cell lung cancer cell line H1299 inhibits the induction of p53 expression by cisplatin (31). However, in alignment with our data, there was no change in basal p53 levels. These data suggest that p53-dependent pathways play an important role in tumor stromal biology.

Our experiments build on this study and demonstrate that additional functional consequences of the p53 status of MSCs include changes in migration efficiency both in vitro and in vivo. Our data also suggest that increased CXCL12 production is not the only important outcome of decreased p53 function in stromal cells. Even in the context of exogenous CXCL12, increased p53 levels lead to impaired motility of MSCs in response to tumor cells. It is likely that the increased rates of tumor formation and progression due to aberrant stromal p53 are a consequence not only of increased CXCL12, but of multiple changes in the stroma. The mechanisms of p53-mediated regulation of CXCL12 expression as well as identification of other important targets of p53 within the tumor stroma are important areas of continued investigation.

In conclusion, the complex interplay between tumor cells and the surrounding non-neoplastic cellular components of solid tumors remains incompletely understood. This study suggests that stromal p53 is a critical mediator of this interaction through multiple pathways. Stromal p53 status influences not only CXCL12 signaling with tumor stromal cells, but also impacts the stromal response to neoplastic cells through other mechanisms.

Acknowledgements

We thank Dr. Arnold Levine and Angie Teresy for providing p53 knockout mice and reagents. The authors received support from the New Jersey Commission on Cancer Research NJCCR-10-1964-CCR-EO (DB and JG) and NJCCR-07-1063-CCR-EO (S.D., predoctoral fellowship).

References

1. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekce BN, Chaplin RE and Andreeff M: Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96: 1593-1603, 2004.
2. Studeny M, Marini FC, Chaplin RE, Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62: 3603-3608, 2002.
3. Shen FH, Visger JM, Balian G, Hurwitz SR and Diduch DR: Systemically administered mesenchymal stromal cell transduced with insulin-like growth factor-I localize to a fracture site and potentiate healing. J Orthop Trauma 16: 651-659, 2002.
4. Klocke GY, Delorme B, Lopez A, Hertoul O, Bonnet P, Charpord P, Eder V and Domenech J: Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia. Stem Cells 24: 2202-2208, 2006.
5. Pittenger MF, Mackay AM, Beck SC, et al: Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147, 1999.
6. Picinich SC, Mishra PJ, Mishra PJ, Glod J and Banerjee D: The therapeutic potential of mesenchymal stem cells. Cell- and tissue-based therapy. Expert Opin Biol Ther 7: 965-973, 2007.
7. Nakamizo A, Marini F, Amano T, et al: Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65: 3307-3318, 2005.
8. Mishra PK: Bone marrow-derived mesenchymal stem cells for treatment of heart failure: is it all paracrine actions and immunomodulation? J Cardiovasc Med (Hagerstown) 9: 122-128, 2008.
9. Menon LG, Picinich S, Koneru R, et al: Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells 25: 520-528, 2007.
10. McFarlin K, Gao X, Liu YB, et al: Bone marrow-derived mesenchymal stromal cells accelerate wound healing in the rat. Wound Repair Regen 14: 471-478, 2006.
11. Kanoub AE, Dash AB, Vo AP, et al: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563, 2007.
12. Mishra PJ, Mishra PJ, Hamenicki R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW and Banerjee D: Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 68: 4331-4339, 2008.
13. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
14. Addadi Y, Moskovits N, Granot D, Lozano G, Carmi Y, Apte RN, Neeman M and Oren M: p53 status in stromal fibroblasts regulates tumour growth in an SDF-1-dependent manner. Cancer Res 70: 9650-9658, 2010.
15. Kiaris H, Chatzistamou I, Trimmis G, Frangou-Plemmenou M, Patiti-Kondi A and Kalofoutis A: Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res 65: 1627-1630, 2005.
16. Houghton J, Li H, Fan X, et al: Mutations in bone marrow-derived stromal stem cells unmask latent malignancy. Stem Cells Dev 19: 1153-1166, 2010.
17. Fukuno K, Shen L, Matsumoto S, Morrison CD, Mutter GL and Eng C: Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets. Cancer Res 64: 7231-7236, 2004.
18. Fukino K, Shen L, Patocs A, Mutter GL and Eng C: Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. JAMA 297: 2103-2111, 2007.
19. Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, Platzer P and Eng C: Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 357: 2543-2551, 2007.

20. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP and Eng C: Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 32: 355-357, 2002.

21. Paterson RF, Ulbright TM, MacLennan GT, et al: Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma. Cancer 98: 1830-1836, 2003.

22. Dudley AC, Shih SC, Cliffe AR, Hida K and Klagsbrun M: Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine. Br J Cancer 99: 118-125, 2008.

23. Alexandrova A, Ivanov A, Chumakov P, Kopnin B and Vasiliev J: Changes in p53 expression in mouse fibroblasts can modify motility and extracellular matrix organization. Oncogene 19: 5826-5830, 2000.

24. Guo F, Gao Y, Wang L and Zheng Y: p19Arf-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 GTPase activities. J Biol Chem 278: 14414-14419, 2003.

25. Molchadsky A, Shats I, Goldfinger N, et al: p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One 3: e3707, 2008.

26. Hinds P, Finlay C and Levine AJ: Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 63: 739-746, 1989.

27. Orimo A, Gupta PB, Sgroi DC, et al: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348, 2005.

28. Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel RE and Jiang WG: Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro and its association with prognosis and survival in human breast cancer. Breast Cancer Res 7: R402-R410, 2005.

29. Hasebe T, Tamura N, Okada N, et al: p53 expression in tumor-stromal fibroblasts is closely associated with the nodal metastasis and outcome of patients with invasive ductal carcinoma who received neoadjuvant therapy. Hum Pathol 41: 262-270, 2010.

30. Trimis G, Chatzistamou I, Politi K, Kiaris H and Papavassiliou AG: Expression of p21\textsuperscript{WAF1/CIP1} in stromal fibroblasts of primary breast tumors. Hum Mol Genet 17: 3596-3600, 2008.

31. Bar J, Feniger-Barish R, Lukashchuk N, et al: Cancer cells suppress p53 in adjacent fibroblasts. Oncogene 28: 933-936, 2009.